SPIA
ACAD icon

Steward Partners Investment Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History

Steward Partners Investment Advisory’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.2K Hold
1,075
– – ﹤0.01% 3275
2026
Q1 		$23.9K Sell
1,075
-352
-25% -$8.41K ﹤0.01% 3143
2025
Q4 		$38.1K Hold
1,427
– – ﹤0.01% 2813
2025
Q3 		$30.5K Buy
1,427
+778
+120% +$18.4K ﹤0.01% 2885
2025
Q2 		$14K Hold
649
– – ﹤0.01% 3057
2025
Q1 		$10.8K Hold
649
– – ﹤0.01% 3059
2024
Q4 		$11.9K Buy
649
+199
+44% +$3.21K ﹤0.01% 3028
2024
Q3 		$6.92K Hold
450
– – ﹤0.01% 3088
2024
Q2 		$7.31K Hold
450
– – ﹤0.01% 2920
2024
Q1 		$8.32K Hold
450
– – ﹤0.01% 2878
2023
Q4 		$14.1K Hold
450
– – ﹤0.01% 2561
2023
Q3 		$9.38K Sell
450
-117
-21% -$3.18K ﹤0.01% 2623
2023
Q2 		$13.6K Buy
567
+467
+467% +$10.4K ﹤0.01% 2466
2023
Q1 		$1.88K Hold
100
– – ﹤0.01% 3031
2022
Q4 		$1.59K Hold
100
– – ﹤0.01% 3063
2022
Q3 		$2K Hold
100
– – ﹤0.01% 2994
2022
Q2 		$1K Hold
100
– – ﹤0.01% 3076
2022
Q1 		$2K Hold
100
– – ﹤0.01% 3061
2021
Q4 		$2K Hold
100
– – ﹤0.01% 2995
2021
Q3 		$2K Hold
100
– – ﹤0.01% 2965
2021
Q2 		$2K Sell
100
-7,270
-99% -$164K ﹤0.01% 6848
2021
Q1 		$190K Buy
7,370
+7,195
+4,111% +$317K ﹤0.01% 1332
2020
Q4 		$9K Hold
175
– – ﹤0.01% 2337
2020
Q3 		$7K Buy
175
+100
+133% +$4.32K ﹤0.01% 2241
2020
Q2 		$4K Hold
75
– – ﹤0.01% 2303
2020
Q1 		$3K Buy
+75
New +$3.09K ﹤0.01% 2189
2019
Q3 		– Sell
-1,600
Closed -$42K – 2605
2019
Q2 		$42K Buy
+1,600
New +$40.9K ﹤0.01% 1397
2018
Q4 		– Sell
-2,600
Closed -$54K – 785
2018
Q3 		$54K Sell
2,600
-4,300
-62% -$67.7K ﹤0.01% 1170
2018
Q2 		$105K Sell
6,900
-100
-1% -$1.78K 0.01% 828
2018
Q1 		$157K Buy
7,000
+350
+5% +$9.69K 0.01% 661
2017
Q4 		$200K Buy
+6,650
New +$213K 0.02% 518

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Steward Partners Investment Advisory's ACAD Position: Q2 2026 in Review

Steward Partners Investment Advisory held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 1,075 shares worth $27.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3275.

Steward Partners Investment Advisory first reported a position in ACAD in Q4 2017 and has held it in 31 quarters since. The position peaked at $200K in Q4 2017. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Steward Partners Investment Advisory held 1,075 shares of Acadia Pharmaceuticals worth $27.2K as of Q2 2026.
  • Steward Partners Investment Advisory left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3275 holding.
  • Steward Partners Investment Advisory first reported a position in Acadia Pharmaceuticals in Q4 2017 and has held it in 31 quarters since.
  • Steward Partners Investment Advisory's Acadia Pharmaceuticals position peaked at $200K in Q4 2017.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.